Amylyx Pharmaceuticals Hires Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager EMEA
26.10.2021 15:50:00 EEST | Business Wire | Press release
Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA). Ms. Hoffmann-Gendebien brings more than 20 years of leadership experience in the pharmaceutical and biotechnology industries with deep expertise in orphan drug development and commercialization. The first European entity of Amylyx, Amylyx Pharmaceuticals EMEA B.V., is incorporated in the Netherlands and is establishing a presence and team in Europe in order to be closer to the patient community, centers of excellence in medicine and regulatory authorities in regions for which Ms. Hoffmann-Gendebien will manage and oversee at Amylyx. Amylyx will establish its EMEA headquarters in the Zuidas district, Amsterdam, and plans a future expansion into the Middle East and Africa markets.
“At Amylyx, we are determined to help people living with ALS around the world. By expanding our organization in Europe, we can build deeper relationships with local ALS communities and understand their unique needs. With Stéphanie’s extensive global commercial and rare disease experience, and talent for developing long lasting partnerships with advocacy groups, researchers and clinicians, we are confident in her ability to lead Amylyx’ European organization,” said Margaret Olinger, Chief Commercial Officer at Amylyx. “Alongside an already impressive track record, we are certain with Stéphanie’s hands-on leadership style and can-do attitude, she will help us build an incredible team and significant presence across the continent. We’re truly honored to have her join the Amylyx team.”
In her career, Ms. Hoffmann-Gendebien has successfully led the launch of two orphan drugs in Europe and directed global market development, global patient advocacy, European market access and European launch planning for two additional orphan drugs. Most recently, Ms. Hoffmann-Gendebien served as managing director and founding partner of GH PARTNERS, a management consulting company providing consulting services for biotechnology companies involved in rare diseases and orphan drug development. GH PARTNERS provided guidance and consulting to companies related to market development, market access, patient advocacy, general management, orphan drug launch planning and commercialization.
“I was inspired by what I learned about the dedication and urgency with which the entire Amylyx team works to effectively advance AMX0035 through the clinical and commercial development process to help the global ALS community,” said Ms. Hoffmann-Gendebien. “Their willingness to listen and learn from advocacy groups to understand the unique needs of people with ALS is astonishing and makes me proud to join the company. Amylyx is at the forefront of advancing new treatments in neurodegenerative diseases and I am delighted to have the opportunity to develop this organization’s European presence and build out an agile team to serve this market.”
Prior to joining Amylyx, Ms. Hoffmann-Gendebien served as vice president, general manager, Europe, Middle East & Africa (EMEA) at Clementia Pharmaceuticals Inc. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals, Inc.) and held roles of increasing responsibility in the therapeutics division Genzyme Europe BV (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies, a role she has held since April 2020, and volunteers with the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient-driven alliance of rare disease patient organizations. Ms. Hoffmann-Gendebien received a bachelor’s degree in chemistry and an MBA from the Université catholique de Louvain in Louvain-la-Neuve, Belgium.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005775/en/
Contact information
Becky Gohsler
Finn Partners
(646) 307-6307
Becky.Gohsler@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom